Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Reporting noninferiority trials--reply.

Pocock SJ, Piaggio G, Altman DG; CONSORT Group.

JAMA. 2013 Apr 17;309(15):1585. doi: 10.1001/jama.2013.3095. No abstract available.

PMID:
23592099
[PubMed - indexed for MEDLINE]
2.

Reporting noninferiority trials.

Aberegg S.

JAMA. 2013 Apr 17;309(15):1584-5. doi: 10.1001/jama.2013.3086. No abstract available.

PMID:
23592098
[PubMed - indexed for MEDLINE]
3.

Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement.

Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group.

JAMA. 2012 Dec 26;308(24):2594-604. doi: 10.1001/jama.2012.87802.

PMID:
23268518
[PubMed - indexed for MEDLINE]
4.

Trials and tribulations of noninferiority: the ximelagatran experience.

Albers GW, Diener HC, Frison L, Grind M, Horrow J, Nevinson M, Olsson SB, Partridge S, Petersen P, Vahanian A, Halperin JL; Executive Steering Committee for the SPORTIF III and V Investigators.

J Am Coll Cardiol. 2006 Sep 5;48(5):1058; author reply 1059. Epub 2006 Aug 17. No abstract available.

PMID:
16949503
[PubMed - indexed for MEDLINE]
Free Article
5.

An orwellian discourse on the meaning and measurement of noninferiority.

Diamond GA, Kaul S.

Am J Cardiol. 2007 Jan 15;99(2):284-7. Epub 2006 Nov 27. Review.

PMID:
17223435
[PubMed - indexed for MEDLINE]
6.

Making sense of noninferiority: a clinical and statistical perspective on its application to cardiovascular clinical trials.

Kaul S, Diamond GA.

Prog Cardiovasc Dis. 2007 Jan-Feb;49(4):284-99. Review.

PMID:
17185116
[PubMed - indexed for MEDLINE]
7.

Three-arm noninferiority trials with a prespecified margin for inference of the difference in the proportions of binary endpoints.

Hida E, Tango T.

J Biopharm Stat. 2013;23(4):774-89. doi: 10.1080/10543406.2013.789893.

PMID:
23799810
[PubMed - indexed for MEDLINE]
8.

How to use a noninferiority trial: users' guides to the medical literature.

Mulla SM, Scott IA, Jackevicius CA, You JJ, Guyatt GH.

JAMA. 2012 Dec 26;308(24):2605-11. doi: 10.1001/2012.jama.11235.

PMID:
23268519
[PubMed - indexed for MEDLINE]
9.

Making statistics boring again.

Berger VW.

Stat Med. 2010 Jun 15;29(13):1458. doi: 10.1002/sim.3884. No abstract available.

PMID:
20527016
[PubMed - indexed for MEDLINE]
10.

SOP 09: Statistical design and analysis.

[No authors listed]

Onkologie. 2003 Oct;26 Suppl 6:43-7. No abstract available.

PMID:
23570186
[PubMed - indexed for MEDLINE]
11.

Use and interpretation of composite end points in orthopaedic trials.

Busse JW, Bhandari M, Ferreira-González I, Montori VM, Guyatt GH.

J Bone Joint Surg Am. 2012 Jul 18;94 Suppl 1:65-9. doi: 10.2106/JBJS.K.01287.

PMID:
22810451
[PubMed - indexed for MEDLINE]
12.

Multiplicity in randomised trials I: endpoints and treatments.

Schulz KF, Grimes DA.

Lancet. 2005 Apr 30-May 6;365(9470):1591-5.

PMID:
15866314
[PubMed - indexed for MEDLINE]
13.

Sample size calculation for a hypothesis test.

Stokes L.

JAMA. 2014 Jul;312(2):180-1. doi: 10.1001/jama.2014.8295. No abstract available.

PMID:
25005655
[PubMed - indexed for MEDLINE]
14.

Mistake on quantifying the indirect treatment effect via surrogate markers by Y. Qu and M. Case Statistics in Medicine 2006; 25:223-231.

Dibaj S, Faghihzadeh S, Jalaie S.

Stat Med. 2010 Aug 30;29(19):2067; author reply 2068. doi: 10.1002/sim.3932. No abstract available.

PMID:
20683897
[PubMed - indexed for MEDLINE]
15.

Addressing multiplicity issues of a composite endpoint and its components in clinical trials.

Huque MF, Alosh M, Bhore R.

J Biopharm Stat. 2011 Jul;21(4):610-34. doi: 10.1080/10543406.2011.551327.

PMID:
21516560
[PubMed - indexed for MEDLINE]
16.

Interpretation and inference in noninferiority randomized controlled trials in drug research.

Wangge G, Klungel OH, Roes KC, de Boer A, Hoes AW, Knol MJ.

Clin Pharmacol Ther. 2010 Sep;88(3):420-3. doi: 10.1038/clpt.2010.134. Epub 2010 Jul 28.

PMID:
20668448
[PubMed - indexed for MEDLINE]
17.

Subgroup analyses in trial reports comparing percutaneous coronary intervention with coronary artery bypass surgery.

Head SJ, Kaul S, Tijssen JG, Serruys PW, Kappetein AP.

JAMA. 2013 Nov 20;310(19):2097-8. doi: 10.1001/jama.2013.281630. No abstract available.

PMID:
24240937
[PubMed - indexed for MEDLINE]
18.

Defining the optimal activated clotting times during percutaneous coronary intervention: aggregate results from 6 randomized, controlled trials.

Helft G, Beygui F, le Feuvre C, Metzger JP.

Circulation. 2001 Nov 27;104(22):E124. No abstract available.

PMID:
11723037
[PubMed - indexed for MEDLINE]
Free Article
19.

Sponsors' participation in conduct and reporting of industry trials: a descriptive study.

Lundh A, Krogsbøll LT, Gøtzsche PC.

Trials. 2012 Aug 24;13:146. doi: 10.1186/1745-6215-13-146.

PMID:
22920226
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Mega-randomized clinical trials for blockbuster drugs--reply.

Ioannidis JP.

JAMA. 2013 Apr 24;309(16):1683. doi: 10.1001/jama.2013.2742. No abstract available.

PMID:
23613069
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk